

Module 1.4.3

Information about the Expert – Clinical

According to his / her respective qualifications the undersigned expert declares hereby to have performed the duties set out in the Article 12 and in accordance with Annex I, Part I 1.4 of Directive 2001/83/EC, as amended.

Clinical:

Name of the expert: Dr. Christian Joukhadar Signature:

Address: Mooslackengasse 17

A-1190 Vienna

Date: 9th May 2018

According to the Annex I of Directive 2001/83/EC as amended, brief information (*curriculum vitae*) on the educational background, training and occupational experience of the expert is attached.

CURRICULUM VITAE



Name: Christian Joukhadar

Citizenship: Austria

Birthdate: February 14, 1970; Vienna, Austria

Permanent Address: work: 1) Beth Israel Deaconess Medical Center
Dept. of Infectious Disease, Boston, MA 02215, USA
Harvard Medical School, Boston, MA 02115, USA
Email: cjoukhad@bidmc.harvard.edu

2) J&P MEDICAL RESEARCH LTD.
Auhofstr. 15/8-9
1130 Vienna, Austria
Phone: (+43 1) 876 043 210
Email: christian.joukhadar@jp-medical-research.com

Current Position: Medical doctor,
Associate Professor (at Harvard University)
Managing Director and Chief Operating Officer
of J&P MEDICAL RESEARCH LTD.

Education:

School-certificate examination ("Reifeprüfung")	June 6, 1988
Student at the Medical University of Vienna, Austria	1988-1995
Member of the Austrian National Rowing Team	1998-1992
Military Service at „Special Force and Military Sports“	1990-1992
General manager in private industry	1989-1992
Assistant to nurses at the Department of Anesthesiology, Medical University of Vienna, Austria	1992-1995
Graded to medical doctor, University of Vienna, Austria	July 10, 1995
Graded to general practitioner	July 31, 1998
Graded to emergency physician	May 1997
Medical doctor at the Department of Clinical	

Pharmacology, Medical University of Vienna, Austria	January 1 st , 1999/June 31, 2007
Lecturer at the “Vienna School of Clinical Research“	2001-2003
Medical doctor at the Department of Cardiology, Division Intensive Care Medicine, Medical University of Vienna, Austria	2001-2004
Head Section of Clinical Pharmacokinetics, Department of Clinical Pharmacology Vienna Medical University of Vienna, Austria	2002/July 31, 2007
Independent consultant for pharmaceutical industry	2001-present
Medical doctor and lecturer at the Institute of Pharmacology Medical University of Vienna, Austria	2003-2006
Habilitation in Clinical Pharmacology at the Medical University of Vienna	March, 2004
Medical doctor at the Division of Infectious Diseases and Chemotherapy, Medical University of Vienna, Austria	2005-2006
Helicopter emergency physician (Salzburg, Austria)	2005 - November 1 st , 2007
Certified Principal Investigator (Austrian Medical Association)	March 13, 2007
Medical doctor at the Division of Pulmonology, Medical University of Vienna, Austria	2006 - July 31, 2007
Head of Facility “Good Laboratory Practice” (GLP)	2006 - July 31, 2007
Managing Director and Chief Operating Officer of J&P MEDICAL RESEARCH LTD.	August 1 st , 2007- ongoing
Graded to specialist in Internal Medicine	September 22, 2007
Visiting Associate Professor at Harvard Medical School, Boston 02115, MA, USA	January 1 st , 2008-Dec.31, 2009
Senior research fellow at Beth Israel Deaconess Medical Center, Boston, MA, (lab. of Prof. Dr. R.C. Moeller jun.)	January 1 st , 2008- ongoing
Editorial Advisory Board Member of the Journal “The Open Antimicrobial Agents Journal”	October 2008- ongoing
Editorial Advisory Board Member of the Journal “Inflammation & Allergy - Drug Targets”	October 2008- ongoing
Editor of the Journal “Pharmacology”	November 2008- ongoing

Editor of the Journal "Pharmacology & Pharmacy"

September 2010- ongoing

C. Joukhadar, JUL. 2010

PUBLICATIONS

peer reviewed original articles only

110. Kovar FM, Marsik CL, **Joukhadar C**, Perkmann T, Haslacher H, Schickbauer T, Kyrle PA, Wagner OF, Endler G. [Coagulation factor VIII levels are associated with long-term survival - interactions with gender in a large hospital-based cohort.](#) *Wien Klin Wochenschr.* 2010 Jun 25. [impact; 0.955]
109. Traunmüller F, Mauric O, Popovic M, **Joukhadar C**. [Rapid and sensitive determination of the antibiotic linezolid in low plasma volumes by high-performance liquid chromatography.](#) *J Chromatogr Sci.* 2010;48(5):325-7. [impact; 1.135]
108. Traunmüller F, Schintler MV, Spindel S, Popovic M, Mauric O, Scharnagl E, **Joukhadar C**. [Linezolid concentrations in infected soft tissue and bone following repetitive doses in diabetic patients with bacterial foot infections.](#) *Int J Antimicrob Agents.* 2010 Jul;36(1):84-6. Epub 2010 Apr 24. [impact; 3.067]
107. Traunmüller F, Schintler MV, Metzler J, Spindel S, Mauric O, Popovic M, Konz KH, Scharnagl E, **Joukhadar C**. [Soft tissue and bone penetration abilities of daptomycin in diabetic patients with bacterial foot infections.](#) *J Antimicrob Chemother.* 2010 Jun;65(6):1252-7. Epub 2010 Apr 7. [impact; 4.328]
106. Matzi V, Lindenmann J, Porubsky C, Kugler SA, Maier A, Dittrich P, Smolle-Jüttner FM, **Joukhadar C**. [Extracellular concentrations of fosfomycin in lung tissue of septic patients.](#) *J Antimicrob Chemother.* 2010 May;65(5):995-8. Epub 2010 Mar 12 [impact; 4.328]
105. Kielstein JT, Eugbers C, Bode-Boeger SM, Martens-Lobenhoffer J, Haller H, **Joukhadar C**, Traunmüller F, Knitsch W, Hafer C, Burkhardt O. [Dosing of daptomycin in intensive care unit patients with acute kidney injury undergoing extended dialysis--a pharmacokinetic study.](#) *Nephrol Dial Transplant.* 2010 May;25(5):1537-41. Epub 2009 Dec 22 [impact; 3.568]
104. **Joukhadar C**, Pillai S, Wennersten C, Moellering RC Jr, Eliopoulos GM. [Lack of Bactericidal Antagonism or Synergism In Vitro Between Oxacillin and Vancomycin Against Methicillin-Susceptible Strains of Staphylococcus Aureus.](#) *Antimicrob Agents Chemother.* 2010 Feb;54(2):773-7. [impact; 4.716]
103. Popovic M, Steinort D, Pillai S, **Joukhadar C**. [Fosfomycin: an old, new friend?](#) *Eur J Clin Microbiol Infect Dis.* 2010 Feb;29(2):127-42 review [impact; 2.866]

102. Kovar FM, Marsik CL, Jilma B, Mannhalter C, **Joukhadar C**, Wagner OF, Endler G. [The inflammatory response is influenced by FXIII VAL 34 LEU polymorphism in a human LPS model.](#) *Wien Klin Wochenschr.* 2009 Aug;121(15-16):515-519. [impact; 0.857]
101. Schintler MV, Traunmüller F, Metzler J, Kreuzwirt G, Spendel S, Mauric O, Popovic M, Scharnagl E, **Joukhadar C**. [High fosfomycin concentrations in bone and peripheral soft tissue in diabetic patients presenting with bacterial foot infection.](#) *J Antimicrob Chemother.* 2009 Sep;64(3):574-8. Epub 2009 Jul 3. [impact; 4.328]
100. Khadzhyrov D, **Joukhadar C**, Peters H. [Plasma and peritoneal dialysate levels during daptomycin therapy for peritonitis.](#) *Am J Kidney Dis.* 2009 May;53(5):911-2. [impact; 4.822]
99. Traunmüller F, Fille M, Thallinger C, **Joukhadar C**. [Multiple-dose pharmacokinetics of telithromycin in peripheral soft tissues.](#) *Int J Antimicrob Agents.* 2009 Jul;34(1):72-5. Epub 2009 Apr 19. [impact; 3.067]
98. **Joukhadar C**, Thallinger C, Pöppel W, Kovar F, Konz KH, Joukhadar SM, Traunmüller F. [Concentrations of voriconazole in healthy and inflamed lung in rats.](#) *Antimicrob Agents Chemother.* 2009 Jun;53(6):2684-6. Epub 2009 Mar 30. [impact; 4.716]
97. Traunmüller F, Thallinger C, Hausdorfer J, Lambers C, Tzaneva S, Kampitsch T, Endler G, **Joukhadar C**. [Tigecycline has no effect on cytokine release in an ex vivo endotoxin model of human whole blood.](#) *Int J Antimicrob Agents.* 2009 Jun;33(6):583-6. Epub 2009 Jan 25 [impact; 3.067]
96. Thallinger C, Skorjanec S, Soleiman A, Tzaneva S, Griss J, Rous W, Pöppel W, Weinlich G, Karimian-Teherani D, **Joukhadar C**. [Orally administered rapamycin, dacarbazine or both for treatment of human melanoma evaluated in severe combined immunodeficiency mice.](#) *Pharmacology.* 2008;82(3):233-8. Epub 2008 Sep 23. [impact; 1.894]
95. Burklein D, Heyn J, Kirchhoff C, Ozimek A, Traunmüller F, **Joukhadar C**, Rothenburger M, Mutschler W, Heindl B. [Analysis of plasma and peritoneal fluid concentrations of daptomycin in a patient with Enterococcus faecium peritonitis.](#) *Int J Antimicrob Agents.* 2008 Oct;32(4):369-71. [impact; 3.067]
94. Ehrlich HJ, Müller M, Oh HM, Tambyah PA, **Joukhadar C**, Montomoli E, Fisher D, Berezuk G, Fritsch S, Löw-Baselli A, Vartian N, Bobrovsky R, Pavlova BG, Pöllabauer EM, Kistner O, Barrett PN; Baxter H5N1 Pandemic Influenza Vaccine Clinical Study Team. [A clinical trial of a whole-virus H5N1 vaccine derived from cell culture.](#) *N Engl J Med.* 2008 Jun 12;358(24):2573-84. [impact; 50.017]
93. Sauermann R, Mayer-Helm BX, Petsch M, Popovic M, Thallinger C, **Joukhadar C**. [Is experimental endotoxaemia in humans suitable for simulating antibiotic pharmacokinetics in sepsis and septic shock? A pilot study using the model compound fosfomycin.](#) *Int J Antimicrob Agents.* 2008 Mar;31(3):291-2. [impact; 3.067]

92. Marsik C, Kazemi-Shirazi L, Schickbauer T, Winkler S, **Joukhadar C**, Wagner OF, Endler G. [C-reactive protein and all-cause mortality in a large hospital-based cohort](#). *Clin Chem*. 2008 Feb;54(2):343-9. [impact; 5.579]
91. Stolle LB, Plock N, **Joukhadar C**, Arpi M, Emmertsen KJ, Buerger C, Riegels-Nielsen P, Kloft C. [Pharmacokinetics of linezolid in bone tissue investigated by in vivo microdialysis](#). *Scand J Infect Dis*. 2008;40(1):24-9. [impact; 1.678]
90. Kaehler S, Marsik C, Heinisch B, Thallinger C, Sauermann R, Kazemi-Shirazi L, Wagner O, **Joukhadar C**. [S-ibuprofen effectively inhibits thromboxane B2 levels and platelet function in an experimental model of lipopolysaccharide-stimulated and non-stimulated whole blood](#). *Pharmacology*. 2008;81(2):181-6. [impact; 1,894]
89. Burkhardt O, **Joukhadar C**, Traunmüller F, Hadem J, Welte T, Kielstein JT. [Elimination of daptomycin in a patient with acute renal failure undergoing extended daily dialysis](#). *J Antimicrob Chemother*. 2008 Jan;61(1):224-5. [impact; 4.328]
88. Thallinger C, Buerger C, Plock N, Kljucar S, Wuenscher S, Sauermann R, Kloft C, **Joukhadar C**. [Effect of severity of sepsis on tissue concentrations of linezolid](#). *J Antimicrob Chemother*. 2008 Jan;61(1):173-6. Epub 2007 Nov 13. [impact; 4.328]
87. Sauermann R, Rothenburger M, Graninger W, **Joukhadar C**. [Daptomycin: a review 4 years after first approval](#). *Pharmacology*. 2008;81(2):79-91. Epub 2007 Oct 16. [impact; 1.894]
86. Thallinger C, Rothenburger M, Marsik C, Wuenscher S, Popovic M, Endler G, Wagner O, **Joukhadar C**. [Daptomycin does not exert immunomodulatory effects in an experimental endotoxin model of human whole blood](#). *Pharmacology*. 2008;81(1):57-62. Epub 2007 Sep 11. [impact; 1.894]
85. Abraham A, Luurtsema G, Bauer M, Karch R, Lubberink M, Pataraiia E, **Joukhadar C**, Kletter K, Lammertsma AA, Baumgartner C, Müller M, Langer O. [Peripheral metabolism of \(R\)-\[¹¹C\]verapamil in epilepsy patients](#). *Eur J Nucl Med Mol Imaging*. 2008 Jan;35(1):116-23. Epub 2007 Sep 11. [impact; 4.532]
84. Sacher J, Mossaheb N, Spindelegger C, Klein N, Geiss-Granadia T, Sauermann R, Lackner E, **Joukhadar C**, Muller M, Kasper S. [Effects of Olanzapine and Ziprasidone on Glucose Tolerance in Healthy Volunteers](#). *Neuropsychopharmacology*. 2007 Aug 22; [Epub ahead of print] [impact; 6.157]

83. Plock N, Buerger C, **Joukhadar C**, Kljucar S, Kloft C. [Does Linezolid inhibit its own metabolism? - Population pharmacokinetics as a tool to explain the observed nonlinearity in both healthy volunteers and septic patients.](#) *Drug Metab Dispos.* 2007 Oct;35(10):1816-23. Epub 2007 Jul 16. [impact; 3.907]
82. Traunmuller F, Zeitlinger M, Zeleny P, Muller M, **Joukhadar C**. [Pharmacokinetics of single- and multiple-dose oral clarithromycin in soft tissues determined by microdialysis.](#) *Antimicrob Agents Chemother.* 2007 Sep;51(9):3185-9. Epub 2007 Jul 2. [impact; 4.309]
81. Thallinger C, Werzowa J, Poepl W, Kovar FM, Pratscher B, Valent P, Quehenberger P, **Joukhadar C**. [Comparison of a Treatment Strategy Combining CCI-779 Plus DTIC Versus DTIC Monotreatment in Human Melanoma in SCID Mice.](#) *J Invest Dermatol.* 2007 May 17; [Epub ahead of print] [impact; 4.829]
80. Langer O, Bauer M, Hammers A, Karch R, Pataraiia E, Koepp MJ, Abraham A, Luurtsema G, Brunner M, Sunder-Plassmann R, Zimprich F, **Joukhadar C**, Gentzsch S, Dudczak R, Kletter K, Muller M, Baumgartner C. [Pharmacoresistance in Epilepsy: A Pilot PET Study with the P-Glycoprotein Substrate R-\[C\]verapamil.](#) *Epilepsia.* 2007 May 1; [Epub ahead of print] [impact; 3.569]
79. Chaurasia CS, Muller M, Bashaw ED, Benfeldt E, Bolinder J, Bullock R, Bungay PM, Delange EC, Derendorf H, Elmquist WF, Hammarlund-Udenaes M, **Joukhadar C**, Kellogg DL Jr, Lunte CE, Nordstrom CH, Rollema H, Sawchuk RJ, Cheung BW, Shah VP, Stahle L, Ungerstedt U, Welty DF, Yeo H. [AAPS-FDA Workshop White Paper: Microdialysis Principles, Application and Regulatory Perspectives.](#) *J Clin Pharmacol.* 2007 May;47(5):589-603. [impact; 2.993]
78. Chaurasia CS, Muller M, Bashaw ED, Benfeldt E, Bolinder J, Bullock R, Bungay PM, Delange EC, Derendorf H, Elmquist WF, Hammarlund-Udenaes M, **Joukhadar C**, Kellogg DL Jr, Lunte CE, Nordstrom CH, Rollema H, Sawchuk RJ, Cheung BW, Shah VP, Stahle L, Ungerstedt U, Welty DF, Yeo H. [AAPS-FDA Workshop White Paper: Microdialysis Principles, Application and Regulatory Perspectives.](#) *Pharm Res.* 2007 May;24(5):1014-25. Epub 2007 Mar 27. [impact; 2.355]
77. Thallinger C, Poepl W, Pratscher B, Mayerhofer M, Valent P, Tappeiner G, **Joukhadar C**. [CCI-779 plus Cisplatin Is Highly Effective against Human Melanoma in a SCID Mouse Xenotransplantation Model.](#) *Pharmacology.* 2007 Mar 22;79(4):207-213 [Epub ahead of print] [impact; 1.195]
76. Sauermann R, Marsik C, Steiner I, Seir K, Civtko T, Zeitlinger M, Wagner O, **Joukhadar C**. [The immunomodulatory effects of fosfomycin in experimental human endotoxemia.](#) *Antimicrob Agents Chemother.* 2007 May;51(5):1879-81. Epub 2007 Mar 12. [impact; 4.390]

75. Zeitlinger MA, Traunmuller F, Abraham A, Muller MR, Erdogan Z, Muller M, **Joukhadar C**. [A pilot study testing whether concentrations of levofloxacin in interstitial space fluid of soft tissues may serve as a surrogate for predicting its pharmacokinetics in lung.](#) *Int J Antimicrob Agents*. 2007 Jan;29(1):44-50. [impact; 2.338]
74. Zeitlinger BS, Zeitlinger M, Leitner I, Muller M, **Joukhadar C**. [Clinical scoring system for the prediction of target site penetration of antimicrobials in patients with sepsis.](#) *Clin Pharmacokinet*. 2007;46(1):75-83. [impact; 4.145]
73. Zeitlinger M, Marsik C, Steiner I, Sauermann R, Seir K, Jilma B, Wagner O, **Joukhadar C**. [Immunomodulatory effects of fosfomycin in an endotoxin model in human blood.](#) *J Antimicrob Chemother*. 2006 Nov 16; [Epub ahead of print] [impact; 3.891]
72. Wagner C, Graninger W, Presterl E, **Joukhadar C**. [The Echinocandins: Comparison of Their Pharmacokinetics, Pharmacodynamics and Clinical Applications.](#) *Pharmacology*. 2006 Oct 17;78(4):161-177 [Epub ahead of print][impact; 1.240]
71. Thallinger C, **Joukhadar C**. [\[Cytochrom-P450 mediated drug interactions caused by antibiotics.\]](#) *Wien Med Wochenschr*. 2006 Sep;156(17-18):508-14. German. [impact; 0.804]
70. Bauer M, Langer O, Dal-Bianco P, Karch R, Brunner M, Abraham A, Lanzenberger R, Hofmann A, **Joukhadar C**, Carminati P, Ghirardi O, Piovesan P, Forloni G, Corrado ME, Lods N, Dudczak R, Auff E, Kletter K, Muller M. [A positron emission tomography microdosing study with a potential antiamyloid drug in healthy volunteers and patients with Alzheimer's disease.](#) *Clin Pharmacol Ther*. 2006 Sep;80(3):216-227. [impact; 8.066]
69. Wagner C, Sauermann R, **Joukhadar C**. [Principles of Antibiotic Penetration into Abscess fluid.](#) *Pharmacology* 2006 Jul 19;78(1):1-10 [impact; 1,240]
68. Buerger C, Plock N, Dehghanyar P, **Joukhadar C**, Kloft C. [Pharmacokinetics of unbound linezolid in plasma and tissue interstitium of critically ill patients after multiple dosing using microdialysis.](#) *Antimicrob Agents Chemother*. 2006 Jul;50(7):2455-63. [impact; 4.153]
67. Abraham A., Angelberger P, Kletter K, Müller M, **Joukhadar C**, Erker T, Langer O: [Synthesis of fluorine-18-labelled 5- and 6-fluoro-2-pyridinamine.](#) *J Labelled Compd Rad*. 2006 49: 345-356 [impact; 0.746]
66. Gattringer R, Meyer B, Heinz G, Guttman C, Zeitlinger M, **Joukhadar C**, Dittrich P, Thalhammer F. [Single-dose pharmacokinetics of fosfomycin during continuous venovenous haemofiltration.](#) *J Antimicrob Chemother*. 2006 Jun 16 [impact; 3.891]

65. Traunmuller F, Steiner I, Zeitlinger M, **Joukhadar C**. [Development of a high-performance liquid chromatography method for the determination of caspofungin with amperometric detection and its application to in vitro microdialysis experiments.](#) *J Chromatogr B Analyt Technol Biomed Life Sci.* 2006 Jun 16 [impact; 2.647]
64. Kaehler ST, Steiner IM, Sauermann R, Scheidl H, Mueller M, **Joukhadar C**. [A bioequivalence study of two oral desmopressin tablet formulations.](#) *Pharmacology.* 2006;77(1):46-52. Epub 2006 Apr 10. [impact; 1.240]
63. Steiner IM, Kaehler ST, Sauermann R, Rinosl H, Muller M, **Joukhadar C**. [Plasma pharmacokinetics of desmopressin following sublingual administration: an exploratory dose-escalation study in healthy male volunteers.](#) *Int J Clin Pharmacol Ther.* 2006 Apr;44(4):172-9. [impact; 1.361]
62. Islinger F, Dehghanyar P, Sauermann R, Burger C, Kloft C, Muller M, **Joukhadar C**. [The effect of food on plasma and tissue concentrations of linezolid after multiple doses.](#) *Int J Antimicrob Agents.* 2006 Feb;27(2):108-12. [impact; 2.221]
61. Thallinger C, Urbauer E, Lackner E, Graselli U, Kostner K, Wolzt M, **Joukhadar C**. [The ability of statins to protect low density lipoprotein from oxidation in hypercholesterolemic patients.](#) *Int J Clin Pharmacol Ther.* 2005 Dec;43(12):551-7. [impact; 1.755]
60. Kulemann V, Bauer M, Graninger W, **Joukhadar C**. [Potential of drug interactions of voriconazole and caspofungin.](#) *Wiener Klinische Wochenschr Magazin* 2005; 5:24-34 [impact; 0.577]
59. Schwalbe O, Buerger C, Plock N, **Joukhadar C**, Kloft C. [Urea as an endogenous surrogate in human microdialysis to determine relative recovery of drugs: Analytics and applications.](#) *J Pharm Biomed Anal.* 2005 Dec 15; [Epub ahead of print] [impact; 1.889]
58. Zeitlinger M, Muller M, **Joukhadar C**. [Lung microdialysis-a powerful tool for the determination of exogenous and endogenous compounds in the lower respiratory tract \(mini-review\).](#) *AAPS J.* 2005 Oct 22;7(3):E600-8. [impact; 1.100]
57. Langer O, Karch R, Muller U, Dobrozemsky G, Abraham A, Zeitlinger M, Lackner E, **Joukhadar C**, Dudczak R, Kletter K, Muller M, Brunner M. [Combined PET and Microdialysis for In Vivo Assessment of Intracellular Drug Pharmacokinetics in Humans.](#) *J Nucl Med.* 2005 Nov;46(11):1835-41. [impact; 5.915]
56. Bauer E, Derfler K, **Joukhadar C**, Druml W. [Citrate kinetics in patients receiving long-term hemodialysis therapy.](#) *Am J Kidney Dis.* 2005 Nov;46(5):903-7. [impact; 4.412]

55. Sauermann R, Karch R, Langenberger H, Kettenbach J, Mayer-Helm B, Petsch M, Wagner C, Sautner T, Gattringer R, Karanikas G, **Joukhadar C**. [Antibiotic abscess penetration: fosfomycin levels measured in pus and simulated concentration-time profiles.](#) *Antimicrob Agents Chemother.* 2005 Nov;49(11):4448-54. [impact; 4.379]
54. Marsik C, Jilma B, **Joukhadar C**, Mannhalter C, Wagner O, Endler G. [The Toll-Like Receptor 4 Asp299Gly and Thr399Ile Polymorphisms Influence the Late Inflammatory Response in Human Endotoxemia.](#) *Clin Chem.* 2005 Nov;51(11):2178-80. [impact; 7.714]
53. Kulemann V, Bauer M, Graninger W, **Joukhadar C**. [Safety and Potential of Drug Interactions of Caspofungin and Voriconazole in Multimorbid Patients.](#) *Pharmacology.* 2005 Sep 28;75(4):165-178 [impact; 1.375]
52. **Joukhadar C**, Dehghanyar P, Traunmuller F, Sauermann R, Mayer-Helm B, Georgopoulos A, Muller M. [Increase of microcirculatory blood flow enhances penetration of ciprofloxacin into soft tissue.](#) *Antimicrob Agents Chemother.* 2005 Oct;49(10):4149 [impact; 4.379]
51. Ziegler S, Kostner K, Thallinger C, Bur A, Brunner M, Wolzt M, **Joukhadar C**. [Wine Ingestion Has No Effect on Lipid Peroxidation Products.](#) *Pharmacology.* 2005 Sep 13;75(3):152-156. [impact; 1.375]
50. **Joukhadar C**, Muller M. [Microdialysis: Current Applications in Clinical Pharmacokinetic Studies and its Potential Role in the Future.](#) *Clin Pharmacokinet.* 2005;44(9):895-913. [impact; 5.195]
49. Zeitlinger MA, Erovic BM, Sauermann R, Georgopoulos A, Muller M, **Joukhadar C**. [Plasma concentrations might lead to overestimation of target site activity of piperacillin in patients with sepsis.](#) *J Antimicrob Chemother.* 2005 Aug 24; [Epub ahead of print] [impact; 3.886]
48. Bauer MM, Gattringer R, **Joukhadar C**. [Fosfomycin im schwer erreichbaren Kompartiment.](#) *Antibiotika Monitor* 2005; 21(1/2):2-7, German.
47. Petsch M, Mayer-Helm BX, Sauermann R, **Joukhadar C**, Kenndler E. [Determination of fosfomycin in pus by capillary zone electrophoresis.](#) *J Chromatogr A.* 2005 Jul 15;1081(1):55-9. [impact; 3.096]
46. Sauermann R, Muller M, **Joukhadar C**. [Die Penetration von Antibiotika in das schwer erreichbare Kompartiment.](#) *Chemotherapie Journal* 2005;14(3):74-8 [impact; 1.413]
45. Traunmuller F, Gattringer R, Zeitlinger MA, Graninger W, Muller M, **Joukhadar C**. [Determination of telithromycin in human plasma and microdialysates by high-performance liquid chromatography.](#) *J Chromatogr B Analyt Technol Biomed L[impact;e Sci.* 2005 Aug 5;822(1-2):133-6 [impact; 2.391]

44. Dehghanyar P, Burger C, Zeitlinger M, Islinger F, Kovar F, Muller M, Kloft C, **Joukhadar C**. Penetration of linezolid into soft tissues of healthy volunteers after single and multiple doses. *Antimicrob Agents Chemother*. 2005 Jun;49(6):2367-71. [impact; 4.379]
43. Bur A, **Joukhadar C**, Klein N, Herkner, Mitulovic G, Schmid R, Agneter E, Muller M, Brunner M. Effect of exercise on transdermal nicotine release in healthy habitual smokers. *Int J Clin Pharmacol Ther*. 2005 May;43(5):239-43 [impact; 1,755] [impact; 1.755]
42. Stetina PM, Madai B, Kulemann V, Kirch W, **Joukhadar C**. Pharmacokinetics of scopolamine in serum and subcutaneous adipose tissue in healthy volunteers. *Int J Clin Pharmacol Ther*. 2005 Mar;43(3):134-9. [impact; 1.755]
41. Langer O, Brunner M, Zeitlinger M, Ziegler S, Muller U, Dobrozemsky G, Lackner E, **Joukhadar C**, Mitterhauser M, Wadsak W, Minar E, Dudczak R, Kletter K, Muller M. In vitro and in vivo evaluation of [(18)F]ciprofloxacin for the imaging of bacterial infections with PET. *Eur J Nucl Med Mol Imaging*. 2005 Feb;32(2):143-50. Epub 2004 Sep 04. [impact; 3.883]
40. Sauermann R, Delle-Karth G, Marsik C, Steiner I, Zeitlinger M, Mayer-Helm BX, Georgopoulos A, Muller M, **Joukhadar C**. Pharmacokinetics and pharmacodynamics of cefpirome in subcutaneous adipose tissue of septic patients. *Antimicrob Agents Chemother*. 2005 Feb;49(2):650-5. [impact; 4.379]
39. Frossard M, Blank D, **Joukhadar C**, Bayegan K, Schmid R, Luger A, Muller M. Interstitial glucose in skeletal muscle of diabetic patients during an oral glucose tolerance test. *Diabet Med*. 2005 Jan;22(1):56-60. [impact; 2.725]
38. **Joukhadar C**, Kulemann V. Mikrodialyse: Bestimmung der Arzneistoff-konzentration im Zielgewebe. *Universum Innere Medizin*. 2004 (05):16, German.
37. Gattringer R, Urbauer E, Traunmuller F, Zeitlinger M, Dehghanyar P, Zeleny P, Graninger W, Muller M, **Joukhadar C**. Pharmacokinetics of telithromycin in plasma and soft tissues after single-dose administration to healthy volunteers. *Antimicrob Agents Chemother*. 2004 Dec;48(12):4650-3. [impact; 4.216]
36. Islinger F, Bouw R, Stahl M, Lackner E, Zeleny P, Brunner M, Muller M, Eichler HG, **Joukhadar C**. Concentrations of gem[impact;loxacin at the target site after a single oral dose in healthy volunteers. *Antimicrob Agents Chemother*. 2004 Nov;48(11):4246-9. [impact; 4.216]
35. Steiner I, **Joukhadar C**. Antibiotika im schwer erreichbaren Kompartiment – Beiträge aus Grundlagenmedizin und Klinik. *Chemother J*. 2004 Oct;13(5):195-202, German. 1,248]

34. Zeitlinger MA, Sauermann R, Traunmuller F, Georgopoulos A, Muller M, **Joukhadar C**. [Impact of plasma protein binding on antimicrobial activity using time-killing curves](#). *J Antimicrob Chemother*. 2004 Nov;54(5):876-80. Epub 2004 Oct 07. [impact; 3.611]
33. Zeitlinger M, Graninger W, **Joukhadar C**. [Pharmacokinetics of the macrolides azithromycin, clarithromycin and roxithromycin in plasma and tissue – are there significant differences?](#) *Wiener Klinische Wochenschr* 2004 (11-12a): 18-24 [impact; 0.901]
32. Petsch M, Mayer-Helm BX, Sauermann R, **Joukhadar C**, Kenndler E. [Capillary electrophoresis analysis of fosfomycin in biological fluids for clinical pharmacokinetic studies](#). *Electrophoresis*. 2004 Jul;25(14):2292-2298. [impact; 3.743]
31. Bellmann R, Kuchling G, Dehghanyar P, Zeitlinger M, Minar E, Mayer BX, Muller M, **Joukhadar C**. [Tissue pharmacokinetics of levofloxacin in human soft tissue infections](#). *Br J Clin Pharmacol*. 2004 May;57(5):563-8. [impact; 2.546]
30. Pfausler B, Spiss H, Dittrich P, Zeitlinger M, Schmutzhard E, **Joukhadar C**. [Concentrations of fosfomycin in the cerebrospinal fluid of neurointensive care patients with ventriculostomy-associated ventriculitis](#). *J Antimicrob Chemother*. 2004 May;53(5):848-52. [impact; 3.611]
29. Steiner IM, Langenberger H, Marsik C, Mayer BX, Fischer M, Georgopoulos A, Muller M, Heinz G, **Joukhadar C**. [Effect of norepinephrine on ceftazidime tissue concentrations in healthy subjects](#). *J Antimicrob Chemother*. 2004 Mar;53(3):506-11. Epub 2004 Jan 28. [impact; 3.611]
28. Endler G, Marsik C, **Joukhadar C**, Marculescu R, Mayr F, Mannhalter C, Wagner OF, Jilma B. [The interleukin-6 \(-174\)C promoter polymorphism does not determine plasma interleukin-6 concentrations in experimental endotoxemia in humans](#). *Clin Chem*. 2004 Jan;50(1):195-200. [impact; 6.501]
27. Sauermann R, Zeitlinger M, Erovic BM, Marsik C, Georgopoulos A, Muller M, Brunner M, **Joukhadar C**. [Pharmacodynamics of piperacillin in severely ill patients evaluated by using a PK/PD model](#). *Int J Antimicrob Agents*. 2003 Dec;22(6):574-578. [impact; 2.064]
26. Zeitlinger MA, Dehghanyar P, Mayer BX, Schenk BS, Neckel U, Heinz G, Georgopoulos A, Muller M, **Joukhadar C**. [Relevance of Soft-Tissue Penetration by Levofloxacin for Target Site Bacterial Killing in Patients with Sepsis](#). *Antimicrob Agents Chemother*. 2003 Nov;47(11):3548-3553. [impact; 4.216]
25. **Joukhadar C**, Schenk B, Kaehler ST, Kollenz CJ, Bauer P, Muller M, Eichler HG. [A replicate study design for testing bioequivalence: a case study on two desmopressin nasal spray preparations](#). *Eur J Clin Pharmacol*. 2003 Nov;59(8-9):631-636. [impact; 2.083]

24. Buerger C, **Joukhadar C**, Muller M, Kloft C. [Development of a liquid chromatography method for the determination of linezolid and its application to in vitro and human microdialysis samples.](#) *J Chromatogr B Analyt Technol Biomed.* 2003 Oct 25;796(1):155-164. [impact; 2.176]
23. Kramer L, Bauer E, **Joukhadar C**, Strobl W, Gendo A, Madl C, Gangl A. [Citrate pharmacokinetics and metabolism in cirrhotic and noncirrhotic critically ill patients.](#) *Crit Care Med.* 2003 Oct;31(10):2450-5. [impact; 4.182]
22. **Joukhadar C**, Stass H, Müller-Zellenberg U, Lackner E, Kovar F, Minar E, Muller M. [Penetration of Mox\[impact;loxacin into Healthy and Inflamed Subcutaneous Adipose Tissues in Humans.](#) *Antimicrob Agents Chemother.* 2003 Oct;47(10):3099-3103. [impact; 4.216]
21. Urbauer E, **Joukhadar C**. [Non-lipid effects of statins: Fact or Fiction?](#) *Wien Med Wochenschr.* 2003;153(11-12):244-9, German. [impact; 0.901]
20. Zeitlinger MA, Marsik C, Georgopoulos A, Muller M, Heinz G, **Joukhadar C**. [Target site bacterial killing of cefpirome and fosfomycin in critically ill patients.](#) *Int J Antimicrob Agents.* 2003 Jun;21(6):562-7. [impact; 2.064]
19. Buerger C, **Joukhadar C**, Muller M, Kloft C. [Individualized therapy through monitoring of drug concentration in the biophase.](#) *Med Monatsschr Pharm.* 2003 May;26(5):158-9.
18. Priglinger U, Delle Karth G, Geppert A, **Joukhadar C**, Graf S, Berger R, Hulsmann M, Spitzauer S, Pabinger I, Heinz G. [Prophylactic anticoagulation with enoxaparin: Is the subcutaneous route appropriate in the critically ill?](#) *Crit Care Med.* 2003 May;31(5):1405-9. [impact; 4.182]
17. **Joukhadar C**, Klein N, Dittrich P, Zeitlinger M, Geppert A, Skhirtladze K, Frossard M, Heinz G, Muller M. [Measurement of fosfomycin concentrations in peripheral compartments in septic patients.](#) *J Antimicrob Chemother.* 2003 May;51(5):1247-52. [impact; 3.611]
16. Herkner H, Klein N, **Joukhadar C**, Lackner E, Langenberger H, Frossard M, Bieglmayer C, Wagner O, Roden M, Muller M. [Transcapillary insulin transfer in human skeletal muscle.](#) *Eur J Clin Invest.* 2003 Feb;33(2):141-6. [impact; 2.530]
15. Jilma B, **Joukhadar C**, Derhaschnig U, Rassoul F, Richter V, Wolzt M, Dorner GT, Petternel V, Wagner OF. [Levels of adhesion molecules do not decrease after 3 months of statin therapy in moderate hypercholesterolaemia.](#) *Clin Sci (Lond).* 2003 Feb;104(2):189-93. [impact; 2.160]

14. Neckel U, **Joukhadar C**, Frossard M, Jäger W, Muller M, Mayer BX. [Simultaneous determination of levofloxacin and ciprofloxacin in microdialysates and plasma by HPLC.](#) *Anal Chim Acta*. 2002; 463:199-206. [impact; 2.588]
13. **Joukhadar C**, Klein N, Mayer BX, Kreischitz N, Delle-Karth G, Palkovits P, Heinz G, Muller M. [Plasma and tissue pharmacokinetics of cefpirome in patients with sepsis.](#) *Crit Care Med*. 2002 Jul;30(7):1478-82. [impact; 4.182]
12. Herkner H, Muller MR, Kreischitz N, Mayer BX, Frossard M, **Joukhadar C**, Klein N, Lackner E, Muller M. [Closed-Chest Microdialysis to Measure Antibiotic Penetration into Human Lung Tissue.](#) *Am J Respir Crit Care Med*. 2002 Jan 15;165(2):273-276. [impact; 8.123]
11. **Joukhadar C**, Klein N, Frossard M, Minar E, Stass H, Lackner E, Herrmann M, Riedmüller E, Muller M. [Angioplasty increases target site concentrations of ciprofloxacin in patients with peripheral arterial occlusive disease.](#) *Clin Pharmacol Ther*. 2001 Dec; 70(6):532-539 [impact; 6.825]
10. **Joukhadar C**, Klein N, Mader RM, Schrolnberger C, Rizovski B, Heere-Ress E, Pehamberger H, Strauchmann N, Jansen B, Muller M. [Penetration of dacarbazine and its active metabolite 5-aminoimidazole-4-carboxamide into cutaneous metastases of human malignant melanoma.](#) *Cancer*. 2001 Oct 15;92(8):2190-6. [impact; 4.434]
9. **Joukhadar C**, Derendorf H, Muller M. Microdialysis. [A novel tool for clinical studies of anti-infective agents.](#) *Eur J Clin Pharmacol*. 2001 June; 57 (3):211-219 [impact; 2.083]
8. **Joukhadar C**, Herranz U, Pernerstorfer T, Assandri A, Klein N, Schrolnberger C, Lackner E, Eichler HG, Muller M. [Pharmacokinetics of emedastine d\[impact;umarate, a new anti-histamic agent in patients with renal impairment.](#) *Eur J Clin Pharmacol*. 2001 Mar; 56 (12):905-910 [impact; 2.083]
7. **Joukhadar C**, Frossard M, Mayer BX, Brunner M, Siostrzonek P, Klein N, Eichler HG, Muller M. [Impaired target site penetration of \$\beta\$ -lactams may account for therapeutic failure in patients with septic shock.](#) *Crit. Care Med*. 2001 Feb;29(2):385-91 [impact; 4.182]
6. **Joukhadar C**, Klein N, Prinz M, Schrolnberger C, Vukovich T, Wolzt M, Schmetterer L, Dorner G. [Similar effects of atorvastatin, simvastatin and pravastatin on thrombogenic and inflammatory parameters in patients with hypercholesterolemia.](#) *Thromb and Haemos*. 2001 Jan;85(1):47-51 [impact; 3.413]
5. Muller M, Brunner B, Hollenstein H, **Joukhadar C**, Schmid R, Minar E, Ehringer H, Eichler HG. [Penetration of ciprofloxacin into the interstitial space of inflamed foot lesions in non-insulin-dependent diabetes mellitus patients.](#) *Antimicrob Agents Chemther*. 1999 Aug;43(8):2056-8 [impact; 4.216]

4. Brunner M, **Joukhadar C**, Schmid R, Erovic B, Eichler HG, Muller M. [Validation of urea as an endogenous reference compound for the in vivo calibration of microdialysis probes.](#) *Life Sci.* 2000 Jul 14;67(8):977-84 [impact; 2.150]
3. Delacher S, Derendorf H, Hollenstein U, Brunner M, **Joukhadar C**, Hofmann S, Georgopoulos A, Eichler HG, Muller M. [A combined in-vivo PK / in-vitro PD approach to simulate target site pharmacodynamics of antibiotics in humans.](#) *J Antimicrob Chemother.* 2000 Nov;46(5):733-39 [impact; 3.611]
2. Frossard M, **Joukhadar C**, Steffen G, Brunner M, Schmid R, Eichler HG, Muller M. [Paracrine effects of angiotensin-converting-enzyme and angiotensin II receptor inhibition on transcapillary glucose transport in humans.](#) *Life Sci.* 2000; 66(10):PL147-54 [impact; 2.150]
1. Frossard M, **Joukhadar C**, Burgmann H, Steffen G, Georgopoulos A, Eichler HG, Muller M. [Distribution and antimicrobial activity of fosfomycin in the interstitial fluid of human soft tissues.](#) *Antimicrob Agents and Chemther.* 2000 Oct;44(10):2728-32 [impact; 4.216]